New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication

PLoS Pathogens

Volumn 11, Issue 12, 2015, Pages

  Knowlson, Sarah ^a   Burlison, John ^a   Giles, Elaine ^a   Fox, Helen ^a   Macadam, Andrew J ^a   Minor, Philip D ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE; LIVE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FECES ANALYSIS; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PHENOTYPIC VARIATION; POLIOMYELITIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TEMPERATURE SENSITIVITY; VACCINE PRODUCTION; VIRAL CLEARANCE; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE; ANIMAL; GENETICS; IMMUNOLOGY; POLIOMYELITIS VIRUS;

ANIMALS; HUMANS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 84953300029     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005316     Document Type: Article

References (20)

1. WHO (2015); http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx (Accessed 14th August 2015)
2. Minor PD, .(2012) The polio eradication programme and issues of the endgame. J Gen Virol. 93 457–474 doi: 10.1099/vir.0.036988-0 22128250
3. WHO(2014a): Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines(inactivated);http://www.who.int/biologicals/vaccines/Annex3_IPV_Recommendations_eng.pdf?ua=1(accessed 14th August 2015)
4. WHO(2014b). Polio eradication and end game strategic plan. (2015)http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_A4.pdf (accessed August 18th 2015)
5. WHO (2014c) Global action plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of OPV use. Geneva: World Health Organization; 2014, available at: http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/GAPIII_2014.pdf (accessed 14th August 2015)
6. Heymann DL, Sutter RW, Aylward RB, (2005). A global call for new polio vaccines. Nature 434, 699–700 15815604
7. Macadam AJ, Ferguson G, Stone DM, Meredith J, Knowlson S, Auda G, Almond JW, Minor PD, . (2006) Rational design of genetically stable, live attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J. Virol, 80; 8653–8663 16912313
8. Pipkin P. A., Wood D. J., Racaniello V. R., Minor P. D., (1993). Characterisation of L cells expressing the human poliovirus receptor for the specific detection of polioviruses in vitro. J.Virol.Methods 41, 333–340. 8386181
9. WHO (2014d). Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (oral, live, attenuated) ECBS 63rd report; TRS 980, 51–140 http://www.who.int/biologicals/WHO_TRS_980_WEB.pdf?ua=1 (accessed August 14th 2015)
10. Rowe A., Ferguson G. L., Minor P. D., Macadam A. J., (2000). Coding changes in the poliovirus protease 2A compensate for 5'NCR domain V disruptions in a cell-specific manner. Virology 269, 284–293 10753707
11. Martin J., Crossland G., Wood D. J., Minor P. D., (2003). Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J.Gen.Virol. 84, 1781–1788. 12810872
12. Singer C, Knauert F, Bushar G, Klutch M, Lundquist R, Quinnan GV, Jr1989. Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies. J. Biol. Stand. 17:137–150. 2541133
13. van Steenis G., van Wezel A.L., Sekhuis V.M., 1981. Potency testing of killed polio vaccine in rats. Dev Biol Stand 47; 119–128 6262142
14. Shimizu H, Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan (2014) Vaccine. 2014 Nov 21. pii: S0264-410X(14)01540-0. doi: 10.1016/j.vaccine.2014.11.015 [Epub ahead of print] (accessed August 14th 2015)
15. Sabin A.B, . (1956). Pathogenesis of poliomyelitis: reappraisal in the light of new data. Science, 123: 1151–1157. 13337331
16. Minor PD, (2015) Live attenuated vaccines: historical successes and current challenges. Virology 479–480: 370–392
17. Macadam A. J., Ferguson G., Burlison J., Stone D., Skuce R., Almond J. W., Minor P. D., (1992). Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. Virology 189, 415–422. 1641974
18. Macadam A. J., Ferguson G., Arnold C., Minor P. D., (1991). An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain. J.Virol. 65, 5225–5231 1654440
19. Westrop G. D., Wareham K. A., Evans D. M., Dunn G., Minor P. D., Magrath D. I., Taffs F., Marsden S., Skinner M. A., Schild G. C., , and. (1989). Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J.Virol. 63, 1338–1344. 2536836
20. van der Werf S., Bradley J., Wimmer E., Studier F. W., Dunn J. J., 1986. Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase. Proc Natl Acad Sci U S A 83:2330–4. 3010307